| Business Summary | | KV
Pharmaceutical
Company
is
engaged
in
the
area
of
drug
delivery
technologies
that
enhance
the
effectiveness
of
new
therapeutic
agents,
existing
pharmaceutical
products
and
nutritional
supplements.
The
Company
has
developed
and
patented
a
wide
variety
of
drug
delivery
and
formulation
technologies
in
four
principal
areas:
controlled
release,
oral
and
topical
site-specific,
quick
dissolving
tablets
and
tastemasking
systems.
The
Company
uses
these
systems
in
the
development
of
the
branded
and
generic
products
it
markets,
as
well
as
the
products
of
its
pharmaceutical
marketing
licensees. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | KV
Pharmaceutical
is
engaged
in
the
area
of
drug
delivery
technologies
which
enhance
the
effectiveness
of
new
therapeutic
agents,
existing
pharmaceutical
products
and
nutritional
supplements.
For
the
three
months
ended
6/30/01,
revenues
rose
23%
to
$47.6
million.
Net
income
applicable
to
Common
increased
33%
to
$5.6
million.
Revenues
reflect
higher
sales
of
branded
and
specialty
generic
products.
Earnings
also
reflect
higher
interest
income. | More
from
Market Guide: Significant
Developments |
| Officers | | | FY2001
Compensation | | Pay | Exer | |
| Victor Hermelin, 87 Chairman | $295K | $2.7M | Marc Hermelin, 59 Vice
Chairman, CEO | 2.1M | 1.8M | Gerald Mitchell, 62 CFO,
VP, Treasurer | 209K | 174K | Alan Johnson, 66 Sr.
VP of Corp. Growth and Strategic Devel., Sec., Director | 392K | -- | Raymond Chiostri, 67 VP
and Group Pres | 260K | -- | Dollar
amounts are as of 31-Mar-2001 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|